Back to Search
Start Over
Single-Entity Hydrocodone Extended-Release Capsules in Opioid-Tolerant Subjects with Moderate-to-Severe Chronic Low Back Pain: A Randomized Double-Blind, Placebo-Controlled Study.
- Source :
-
Pain Medicine . Jun2014, Vol. 15 Issue 6, p975-985. 10p. 1 Black and White Photograph, 2 Diagrams, 6 Charts, 2 Graphs. - Publication Year :
- 2014
-
Abstract
- Objective A single-agent, extended-release formulation of hydrocodone (HC) has been developed for treatment of chronic moderate-to-severe pain. This study was designed to examine the safety and efficacy of HC extended release in opioid-experienced adults with moderate-to-severe chronic low back pain (CLBP). Methods This multicenter, enriched enrollment, randomized withdrawal study comprised an open-label conversion/titration phase (≤6 weeks) followed by placebo-controlled, double-blind treatment (12 weeks). During the conversion/titration phase, subjects (N = 510) converted from their current opioid and were titrated to a stabilized dose of HC extended release (20−100 mg every 12 hours). During treatment, subjects (N = 151 per group) received HC extended release or placebo; rescue medication was permitted. The primary efficacy end point was mean change in average pain intensity from baseline to day 85. Response rates (30% pain improvement) and satisfaction ( Subject Global Assessment of Medication) were assessed. Results Demographic and baseline characteristics were similar between groups. Mean ± SD change in average pain intensity score from baseline to day 85 was significantly lower in the HC extended-release treatment group vs placebo (0.48 ± 1.56 vs 0.96 ± 1.55; P = 0.008). Significantly more responders were in the treatment group (68% vs 31%; P < 0.001). Mean Subject Global Assessment of Medication scores increased significantly (0.8 ± 1.3 vs 0.0 ± 1.4; P < 0.0001), indicating greater satisfaction with HC extended release. The adverse event profile was consistent with other opioids. Conclusions Extended-release HC is well tolerated and effective, without acetaminophen-associated risks of liver toxicity, for treatment of CLBP. [ABSTRACT FROM AUTHOR]
- Subjects :
- *ANALYSIS of covariance
*BACKACHE
*CHI-squared test
*CHRONIC diseases
*CODEINE
*CONTROLLED release preparations
*STATISTICAL correlation
*FISHER exact test
*NARCOTICS
*HEALTH outcome assessment
*RESEARCH funding
*T-test (Statistics)
*RANDOMIZED controlled trials
*TREATMENT effectiveness
*BLIND experiment
*DESCRIPTIVE statistics
*KAPLAN-Meier estimator
*LOG-rank test
Subjects
Details
- Language :
- English
- ISSN :
- 15262375
- Volume :
- 15
- Issue :
- 6
- Database :
- Academic Search Index
- Journal :
- Pain Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 96775089
- Full Text :
- https://doi.org/10.1111/pme.12377